The result is a paradox. Even before the HTA Review is formally concluded, announced, and implemented, the environment it was meant to reform has already worsened. Expectations that the review would stabilise or improve conditions now need to be recalibrated. The baseline has moved, and not in a favourable direction. …
To what extent does the system even see itself as bound by external review?
March 25, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Arrotex Pharmaceuticals appoints experienced industry executive as CMO
August 4, 2026 - - Latest News -
The risk to patients is that new pricing policies could swamp any benefit from the HTA Review
August 4, 2026 - - Latest News -
Potential merger could create a new global oncology powerhouse
August 3, 2026 - - Latest News -
The HTA Review and the 'Abilene paradox' - when everyone argues for reforms that nobody wants
August 3, 2026 - - Latest News -
First new brain cancer treatment listed on PBS after more than 20 years
August 3, 2026 - - Latest News -
Funding for new chemotherapy-free immunotherapy combination for follicular lymphoma
August 3, 2026 - - Latest News -
Listing offers treatment option for Australians with tumour induced osteomalacia
August 3, 2026 - - Latest News